IRLAB Therapeutics – executive interview

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — 7 videos in collection

More on this equity

IRLAB Therapeutics is a Sweden-based biotech company focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its integrative screening process technology platform. Its two lead assets, mesdopetam and pirepemat, are in late-stage clinical trials for the symptomatic treatment of Parkinson’s disease (PD). PD is characterised by a triad of cardinal motor symptoms, although non-motor symptoms are as debilitating and remain undertreated. Despite substantial efforts to develop disease-modifying approaches in PD, symptomatic treatment remains the mainstay.

In this interview, CEO Gunnar Olsson provides a recap of IRLAB’s ongoing central nervous system efforts and pipeline.


You may also be interested in these:

Healthcare

IRLAB Therapeutics – executive interview

Healthcare

IRLAB Therapeutics – executive interview

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.